{"transactions":[{"id":733214,"issuer":{"id":275,"kind":"organization","name":"Zenas BioPharma, Inc.","symbol":"ZBIO"},"owners":[{"id":37101,"kind":"person","name":"Lu Hongbo","position":1,"cik":"0001767584","reported_name":"Lu Hongbo","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2026-06-17T22:03:24.000Z","date":"2026-06-15","kind":"grant","planned":false,"acquired":true,"shares":18500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option vests as to 100% of the underlying shares of common stock on June 15, 2027, the first anniversary of the vesting commencement date, subject to continued service."}],"balance_after":18500,"derivative":{"exercise_price":18.71,"expiration_date":"2036-06-15","underlying":"Common Stock","underlying_shares":18500},"source":{"system":"sec-edgar","filing":"0001104659-26-075257","document":"tm2618042-9_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1767584/000110465926075257/tm2618042-9_4seq1.xml","form_type":"4"}},{"id":779900,"issuer":{"id":3472,"kind":"organization","name":"ARROWHEAD PHARMACEUTICALS, INC."},"owners":[{"id":37101,"kind":"person","name":"Lu Hongbo","position":1,"cik":"0001767584","reported_name":"Lu Hongbo","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-05-14T23:05:44.000Z","date":"2026-05-12","kind":"sale","planned":true,"acquired":false,"shares":2970,"price":76.88,"value":228333.6,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Shares were sold pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes previously reported shares of common stock underlying Restricted Stock Units granted to the Reporting person, a portion of which are still subject to certain vesting conditions."}],"balance_after":52012,"source":{"system":"sec-edgar","filing":"0001767584-26-000002","document":"wk-form4_1778799941.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/879407/000176758426000002/wk-form4_1778799941.xml","form_type":"4"}},{"id":818771,"issuer":{"id":275,"kind":"organization","name":"Zenas BioPharma, Inc.","symbol":"ZBIO"},"owners":[{"id":37101,"kind":"person","name":"Lu Hongbo","position":1,"cik":"0001767584","reported_name":"Lu Hongbo","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-04-02T21:02:16.000Z","date":"2026-03-31","kind":"purchase","planned":false,"acquired":true,"shares":3768,"price":18.63,"value":70197.84,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"The reported securities are owned directly by NEXTBio Master Fund LP or NEXTBio Evergreen LLC and may be deemed to be indirectly beneficially owned by (i) NEXTBio Capital LLC, the general partner of NEXTBio Master Fund LP (with respect to such securities directly owned by NEXTBio Master Fund LP), (ii) NEXTBio Capital Evergreen GP LLC, the managing member of NEXTBio Evergreen LLC (with respect to such securities directly owned by NEXTBio Evergreen LLC), (iii) NEXTBio Capital Management LP, the investment manager to NEXTBio Master Fund LP and NEXTBio Evergreen LLC, and (iv) Hongbo Lu, a managing member of NEXTBio Capital LLC and NEXTBio Capital Evergreen GP LLC."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The Reporting Person disclaims beneficial ownership of the reported securities except to the extent of their pecuniary interest therein, and this report shall not be deemed an admission that the Reporting Person is the beneficial owner of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose."}],"balance_after":426736,"source":{"system":"sec-edgar","filing":"0001104659-26-039240","document":"tm2611015-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1767584/000110465926039240/tm2611015-1_4seq1.xml","form_type":"4"}},{"id":823887,"issuer":{"id":275,"kind":"organization","name":"Zenas BioPharma, Inc.","symbol":"ZBIO"},"owners":[{"id":37101,"kind":"person","name":"Lu Hongbo","position":1,"cik":"0001767584","reported_name":"Lu Hongbo","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-03-31T21:00:23.000Z","date":"2026-03-31","kind":"purchase","planned":false,"acquired":true,"shares":75000,"price":20,"value":1500000.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Acquired in an underwritten public offering, pursuant to which Zenas BioPharma, Inc. sold shares of common stock at a purchase price of $20.00 per share."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"The reported securities are owned directly by NEXTBio Master Fund LP or NEXTBio Evergreen LLC and may be deemed to be indirectly beneficially owned by (i) NEXTBio Capital LLC, the general partner of NEXTBio Master Fund LP (with respect to such securities directly owned by NEXTBio Master Fund LP), (ii) NEXTBio Capital Evergreen GP LLC, the managing member of NEXTBio Evergreen LLC (with respect to such securities directly owned by NEXTBio Evergreen LLC), (iii) NEXTBio Capital Management LP, the investment manager to NEXTBio Master Fund LP and NEXTBio Evergreen LLC, and (iv) Hongbo Lu, a managing member of NEXTBio Capital LLC and NEXTBio Capital Evergreen GP LLC."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F3","text":"The Reporting Person disclaims beneficial ownership of the reported securities except to the extent of their pecuniary interest therein, and this report shall not be deemed an admission that the Reporting Person is the beneficial owner of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The reported securities are owned directly by NEXTBio Master Fund LP or NEXTBio Evergreen LLC and may be deemed to be indirectly beneficially owned by (i) NEXTBio Capital LLC, the general partner of NEXTBio Master Fund LP (with respect to such securities directly owned by NEXTBio Master Fund LP), (ii) NEXTBio Capital Evergreen GP LLC, the managing member of NEXTBio Evergreen LLC (with respect to such securities directly owned by NEXTBio Evergreen LLC), (iii) NEXTBio Capital Management LP, the investment manager to NEXTBio Master Fund LP and NEXTBio Evergreen LLC, and (iv) Hongbo Lu, a managing member of NEXTBio Capital LLC and NEXTBio Capital Evergreen GP LLC."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The Reporting Person disclaims beneficial ownership of the reported securities except to the extent of their pecuniary interest therein, and this report shall not be deemed an admission that the Reporting Person is the beneficial owner of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose."}],"balance_after":422968,"source":{"system":"sec-edgar","filing":"0001104659-26-037865","document":"tm2610681-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1767584/000110465926037865/tm2610681-1_4seq1.xml","form_type":"4"}},{"id":904565,"issuer":{"id":275,"kind":"organization","name":"Zenas BioPharma, Inc.","symbol":"ZBIO"},"owners":[{"id":37101,"kind":"person","name":"Lu Hongbo","position":1,"cik":"0001767584","reported_name":"Lu Hongbo","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-02-13T22:35:50.000Z","date":"2026-02-11","kind":"purchase","planned":false,"acquired":true,"shares":25985,"price":22.5,"value":584662.5,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F1","text":"The reported securities are owned directly by NEXTBio Master Fund LP or NEXTBio Evergreen LLC and may be deemed to be indirectly beneficially owned by (i) NEXTBio Capital LLC, the general partner of NEXTBio Master Fund LP (with respect to such securities directly owned by NEXTBio Master Fund LP), (ii) NEXTBio Capital Evergreen GP LLC, the managing member of NEXTBio Evergreen LLC (with respect to such securities directly owned by NEXTBio Evergreen LLC), (iii) NEXTBio Capital Management LP, the investment manager to NEXTBio Master Fund LP and NEXTBio EverGreen LLC, and (iv) Hongbo Lu, a managing member of NEXTBio Capital LLC and NEXTBio Capital Evergreen GP LLC."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"The Reporting Person disclaims beneficial ownership of the reported securities except to the extent of their pecuniary interest therein, and this report shall not be deemed an admission that the Reporting Person is the beneficial owner of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"The reported securities are owned directly by NEXTBio Master Fund LP or NEXTBio Evergreen LLC and may be deemed to be indirectly beneficially owned by (i) NEXTBio Capital LLC, the general partner of NEXTBio Master Fund LP (with respect to such securities directly owned by NEXTBio Master Fund LP), (ii) NEXTBio Capital Evergreen GP LLC, the managing member of NEXTBio Evergreen LLC (with respect to such securities directly owned by NEXTBio Evergreen LLC), (iii) NEXTBio Capital Management LP, the investment manager to NEXTBio Master Fund LP and NEXTBio EverGreen LLC, and (iv) Hongbo Lu, a managing member of NEXTBio Capital LLC and NEXTBio Capital Evergreen GP LLC."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The Reporting Person disclaims beneficial ownership of the reported securities except to the extent of their pecuniary interest therein, and this report shall not be deemed an admission that the Reporting Person is the beneficial owner of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose."}],"balance_after":347968,"source":{"system":"sec-edgar","filing":"0001104659-26-015387","document":"tm266411-2_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1767584/000110465926015387/tm266411-2_4seq1.xml","form_type":"4"}},{"id":963711,"issuer":{"id":3472,"kind":"organization","name":"ARROWHEAD PHARMACEUTICALS, INC."},"owners":[{"id":37101,"kind":"person","name":"Lu Hongbo","position":1,"cik":"0001767584","reported_name":"Lu Hongbo","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-12-18T23:40:14.000Z","date":"2025-12-16","kind":"grant","planned":false,"acquired":true,"shares":7819,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares underlying restricted stock units, which shares will vest in one installment on the first anniversary of the grant date, subject to the Reporting Person's continued service to the Issuer on such date."}],"balance_after":54982,"source":{"system":"sec-edgar","filing":"0001767584-25-000004","document":"wk-form4_1766101211.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/879407/000176758425000004/wk-form4_1766101211.xml","form_type":"4"}},{"id":1020672,"issuer":{"id":275,"kind":"organization","name":"Zenas BioPharma, Inc.","symbol":"ZBIO"},"owners":[{"id":37101,"kind":"person","name":"Lu Hongbo","position":1,"cik":"0001767584","reported_name":"Lu Hongbo","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-10-09T19:37:06.000Z","date":"2025-10-07","kind":"purchase","planned":false,"acquired":true,"shares":263160,"price":19,"value":5000040.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"The reported securities are owned directly by NEXTBio Master Fund LP or NextBio Evergreen LLC and may be deemed to be indirectly beneficially owned by (i) NEXTBio Capital LLC, the general partner of NEXTBio Master Fund LP (with respect to such securities directly owned by NEXTBio Master Fund LP), (ii) NEXTBio Capital Evergreen GP LLC, the managing member of NEXTBio Evergreen LLC (with respect to such securities directly owned by NextBio Evergreen LLC), (iii) NEXTBio Capital Management LP, the investment manager to NEXTBio Master Fund LP and NextBio Evergreen LLC, and (iv) Hongbo Lu, a managing member of NEXTBio Capital LLC and NEXTBio Capital Evergreen GP LLC."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F3","text":"(Continued from footnote 2) The Reporting Person disclaims beneficial ownership of the reported securities except to the extent of their pecuniary interest therein, and this report shall not be deemed an admission that the Reporting Person is the beneficial owner of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The reported securities are owned directly by NEXTBio Master Fund LP or NextBio Evergreen LLC and may be deemed to be indirectly beneficially owned by (i) NEXTBio Capital LLC, the general partner of NEXTBio Master Fund LP (with respect to such securities directly owned by NEXTBio Master Fund LP), (ii) NEXTBio Capital Evergreen GP LLC, the managing member of NEXTBio Evergreen LLC (with respect to such securities directly owned by NextBio Evergreen LLC), (iii) NEXTBio Capital Management LP, the investment manager to NEXTBio Master Fund LP and NextBio Evergreen LLC, and (iv) Hongbo Lu, a managing member of NEXTBio Capital LLC and NEXTBio Capital Evergreen GP LLC."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"(Continued from footnote 2) The Reporting Person disclaims beneficial ownership of the reported securities except to the extent of their pecuniary interest therein, and this report shall not be deemed an admission that the Reporting Person is the beneficial owner of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose."}],"balance_after":321983,"source":{"system":"sec-edgar","filing":"0000919574-25-006031","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1767584/000091957425006031/ownership.xml","form_type":"4"}},{"id":1020671,"issuer":{"id":275,"kind":"organization","name":"Zenas BioPharma, Inc.","symbol":"ZBIO"},"owners":[{"id":37101,"kind":"person","name":"Lu Hongbo","position":1,"cik":"0001767584","reported_name":"Lu Hongbo","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-10-09T19:37:06.000Z","date":"2024-09-13","kind":"purchase","planned":false,"acquired":true,"shares":58823,"price":17,"value":999991.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F1","text":"The reported securities are owned directly by NEXTBio Master Fund LP and may be deemed to be indirectly beneficially owned by (i) NEXTBio Capital LLC, the general partner of NEXTBio Master Fund LP, (ii) NEXTBio Capital Management LP, the investment manager to NEXTBio Master Fund LP, and (iii) Hongbo Lu, a managing member of NEXTBio Capital LLC. The Reporting Person disclaims beneficial ownership of the reported securities except to the extent of their pecuniary interest therein, and this report shall not be deemed an admission that the Reporting Person is the beneficial owner of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"The reported securities are owned directly by NEXTBio Master Fund LP and may be deemed to be indirectly beneficially owned by (i) NEXTBio Capital LLC, the general partner of NEXTBio Master Fund LP, (ii) NEXTBio Capital Management LP, the investment manager to NEXTBio Master Fund LP, and (iii) Hongbo Lu, a managing member of NEXTBio Capital LLC. The Reporting Person disclaims beneficial ownership of the reported securities except to the extent of their pecuniary interest therein, and this report shall not be deemed an admission that the Reporting Person is the beneficial owner of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose."}],"balance_after":58823,"source":{"system":"sec-edgar","filing":"0000919574-25-006031","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1767584/000091957425006031/ownership.xml","form_type":"4"}},{"id":1112810,"issuer":{"id":49595,"kind":"organization","name":"Terns Pharmaceuticals, Inc.","symbol":"TERN"},"owners":[{"id":37101,"kind":"person","name":"Lu Hongbo","position":1,"cik":"0001767584","reported_name":"Lu Hongbo","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-06-12T21:44:19.000Z","date":"2025-06-11","kind":"grant","planned":false,"acquired":true,"shares":45000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option will vest in full on the earlier of (i) the first anniversary of the date of grant and (ii) immediately prior to the Annual Meeting following the date of grant."}],"balance_after":45000,"derivative":{"exercise_price":4.1,"expiration_date":"2035-06-10","underlying":"Common Stock","underlying_shares":45000},"source":{"system":"sec-edgar","filing":"0001562180-25-004759","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1767584/000156218025004759/primarydocument.xml","form_type":"4"}},{"id":1112809,"issuer":{"id":275,"kind":"organization","name":"Zenas BioPharma, Inc.","symbol":"ZBIO"},"owners":[{"id":37101,"kind":"person","name":"Lu Hongbo","position":1,"cik":"0001767584","reported_name":"Lu Hongbo","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-06-12T20:31:15.000Z","date":"2025-06-10","kind":"grant","planned":false,"acquired":true,"shares":18500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option vests as to 100% of the underlying shares of common stock on June 10, 2026, the first anniversary of the vesting commencement date, subject to continued service."}],"balance_after":18500,"derivative":{"exercise_price":11.94,"expiration_date":"2035-06-10","underlying":"Common Stock","underlying_shares":18500},"source":{"system":"sec-edgar","filing":"0001104659-25-058918","document":"tm2517684-2_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1767584/000110465925058918/tm2517684-2_4seq1.xml","form_type":"4"}},{"id":1287004,"issuer":{"id":49595,"kind":"organization","name":"Terns Pharmaceuticals, Inc.","symbol":"TERN"},"owners":[{"id":37101,"kind":"person","name":"Lu Hongbo","position":1,"cik":"0001767584","reported_name":"Lu Hongbo","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-02-04T00:37:54.000Z","date":"2025-02-01","kind":"grant","planned":false,"acquired":true,"shares":10657,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"This option was issued pursuant to the Issuer's Non-Employee Director Compensation Policy, under which the Reporting Person elected to receive this option in lieu of the Reporting Person's cash retainer fee of $40,000 for 2025."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The option will vest as to 1/12th of the total shares subject thereto on each monthly anniversary measured from January 1, 2025, such that 100% of the shares subject to the option will be fully vested on January 1, 2026."}],"balance_after":10657,"derivative":{"exercise_price":4.46,"expiration_date":"2035-01-31","underlying":"Common Stock","underlying_shares":10657},"source":{"system":"sec-edgar","filing":"0001562180-25-000858","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1767584/000156218025000858/primarydocument.xml","form_type":"4"}},{"id":1324788,"issuer":{"id":3472,"kind":"organization","name":"ARROWHEAD PHARMACEUTICALS, INC."},"owners":[{"id":37101,"kind":"person","name":"Lu Hongbo","position":1,"cik":"0001767584","reported_name":"Lu Hongbo","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-12-20T23:04:35.000Z","date":"2024-12-18","kind":"grant","planned":false,"acquired":true,"shares":16733,"price":22.99,"value":384691.67,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares underlying restricted stock units, which shares will vest in one installment on the first anniversary date."}],"balance_after":47163,"source":{"system":"sec-edgar","filing":"0001628280-24-052268","document":"wk-form4_1734735870.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/879407/000162828024052268/wk-form4_1734735870.xml","form_type":"4"}},{"id":1364384,"issuer":{"id":3472,"kind":"organization","name":"ARROWHEAD PHARMACEUTICALS, INC."},"owners":[{"id":37101,"kind":"person","name":"Lu Hongbo","position":1,"cik":"0001767584","reported_name":"Lu Hongbo","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-11-16T01:34:11.000Z","date":"2024-09-25","kind":"gift","planned":false,"acquired":false,"shares":5650,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"On September 25, 2024, the Reporting Person transferred 5,650 shares of the Issuer's common stock from a jointly-held retirement account to her spouse's individual retirement account for no consideration."}],"balance_after":30430,"source":{"system":"sec-edgar","filing":"0001628280-24-048162","document":"wk-form5_1731720845.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/879407/000162828024048162/wk-form5_1731720845.xml","form_type":"5"}},{"id":1364383,"issuer":{"id":3472,"kind":"organization","name":"ARROWHEAD PHARMACEUTICALS, INC."},"owners":[{"id":37101,"kind":"person","name":"Lu Hongbo","position":1,"cik":"0001767584","reported_name":"Lu Hongbo","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-11-16T01:34:11.000Z","date":"2024-04-18","kind":"purchase","planned":false,"acquired":true,"shares":500,"price":22,"value":11000.0,"ownership":{"direct":true},"footnotes":[{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"Includes previously reported restricted stock units, which are subject to certain vesting conditions."}],"balance_after":36080,"source":{"system":"sec-edgar","filing":"0001628280-24-048162","document":"wk-form5_1731720845.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/879407/000162828024048162/wk-form5_1731720845.xml","form_type":"5"}},{"id":1364382,"issuer":{"id":3472,"kind":"organization","name":"ARROWHEAD PHARMACEUTICALS, INC."},"owners":[{"id":37101,"kind":"person","name":"Lu Hongbo","position":1,"cik":"0001767584","reported_name":"Lu Hongbo","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-11-16T01:34:11.000Z","date":"2024-04-10","kind":"purchase","planned":false,"acquired":true,"shares":500,"price":25,"value":12500.0,"ownership":{"direct":true},"footnotes":[{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"Includes previously reported restricted stock units, which are subject to certain vesting conditions."}],"balance_after":35580,"source":{"system":"sec-edgar","filing":"0001628280-24-048162","document":"wk-form5_1731720845.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/879407/000162828024048162/wk-form5_1731720845.xml","form_type":"5"}},{"id":1364381,"issuer":{"id":3472,"kind":"organization","name":"ARROWHEAD PHARMACEUTICALS, INC."},"owners":[{"id":37101,"kind":"person","name":"Lu Hongbo","position":1,"cik":"0001767584","reported_name":"Lu Hongbo","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-11-16T01:34:11.000Z","date":"2024-04-02","kind":"purchase","planned":false,"acquired":true,"shares":150,"price":27.34,"value":4101.0,"ownership":{"direct":true},"footnotes":[{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"Includes previously reported restricted stock units, which are subject to certain vesting conditions."}],"balance_after":35080,"source":{"system":"sec-edgar","filing":"0001628280-24-048162","document":"wk-form5_1731720845.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/879407/000162828024048162/wk-form5_1731720845.xml","form_type":"5"}},{"id":1364380,"issuer":{"id":3472,"kind":"organization","name":"ARROWHEAD PHARMACEUTICALS, INC."},"owners":[{"id":37101,"kind":"person","name":"Lu Hongbo","position":1,"cik":"0001767584","reported_name":"Lu Hongbo","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-11-16T01:34:11.000Z","date":"2024-03-26","kind":"purchase","planned":false,"acquired":true,"shares":850,"price":27.5,"value":23375.0,"ownership":{"direct":true},"footnotes":[{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"Includes previously reported restricted stock units, which are subject to certain vesting conditions."}],"balance_after":34930,"source":{"system":"sec-edgar","filing":"0001628280-24-048162","document":"wk-form5_1731720845.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/879407/000162828024048162/wk-form5_1731720845.xml","form_type":"5"}},{"id":1364379,"issuer":{"id":3472,"kind":"organization","name":"ARROWHEAD PHARMACEUTICALS, INC."},"owners":[{"id":37101,"kind":"person","name":"Lu Hongbo","position":1,"cik":"0001767584","reported_name":"Lu Hongbo","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-11-16T01:34:11.000Z","date":"2024-03-22","kind":"purchase","planned":false,"acquired":true,"shares":400,"price":28,"value":11200.0,"ownership":{"direct":true},"footnotes":[{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"Includes previously reported restricted stock units, which are subject to certain vesting conditions."}],"balance_after":34080,"source":{"system":"sec-edgar","filing":"0001628280-24-048162","document":"wk-form5_1731720845.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/879407/000162828024048162/wk-form5_1731720845.xml","form_type":"5"}},{"id":1404493,"issuer":{"id":275,"kind":"organization","name":"Zenas BioPharma, Inc.","symbol":"ZBIO"},"owners":[{"id":37101,"kind":"person","name":"Lu Hongbo","position":1,"cik":"0001767584","reported_name":"Lu Hongbo","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-09-17T23:52:28.000Z","date":"2024-09-13","kind":"purchase","planned":false,"acquired":true,"shares":58823,"price":17,"value":999991.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"The reported securities are owned directly by NEXTBio Master Fund LP and may be deemed to be indirectly beneficially owned by (i) NEXTBio Capital LLC, the general partner of NEXTBio Master Fund LP, (ii) NEXTBio Capital Management LP, the investment manager to NEXTBio Master Fund LP, and (iii) Hongbo Lu, a managing member of NEXTBio Capital LLC. The Reporting Person disclaims beneficial ownership of the reported securities except to the extent of their pecuniary interest therein, and this report shall not be deemed an admission that the Reporting Person is the beneficial owners of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose."}],"balance_after":58823,"source":{"system":"sec-edgar","filing":"0000919574-24-005530","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1767584/000091957424005530/ownership.xml","form_type":"4"}},{"id":1404492,"issuer":{"id":49595,"kind":"organization","name":"Terns Pharmaceuticals, Inc.","symbol":"TERN"},"owners":[{"id":37101,"kind":"person","name":"Lu Hongbo","position":1,"cik":"0001767584","reported_name":"Lu Hongbo","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-09-17T23:48:06.000Z","date":"2024-09-12","kind":"purchase","planned":false,"acquired":true,"shares":285714,"price":10.5,"value":2999997.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The reported securities are owned directly by NEXTBio Opportunity Adapt LLC and may be deemed to be indirectly beneficially owned by (i) NEXTBio Capital Opportunity Adapt GP, LLC, the managing member of NEXTBio Opportunity Adapt LLC, and (ii) Hongbo Lu, a managing member of NEXTBio Capital Opportunity Adapt GP, LLC. The Reporting Person disclaims beneficial ownership of the reported securities except to the extent of their pecuniary interest therein, and this report shall not be deemed an admission that the Reporting Person is the beneficial owners of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose."}],"balance_after":476190,"source":{"system":"sec-edgar","filing":"0000919574-24-005529","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1767584/000091957424005529/ownership.xml","form_type":"4"}},{"id":1404491,"issuer":{"id":49595,"kind":"organization","name":"Terns Pharmaceuticals, Inc.","symbol":"TERN"},"owners":[{"id":37101,"kind":"person","name":"Lu Hongbo","position":1,"cik":"0001767584","reported_name":"Lu Hongbo","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-09-17T23:48:06.000Z","date":"2024-09-12","kind":"purchase","planned":false,"acquired":true,"shares":190476,"price":10.5,"value":1999998.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"The reported securities are owned directly by NEXTBio Master Fund LP and may be deemed to be indirectly beneficially owned by (i) NEXTBio Capital LLC, the general partner of NEXTBio Master Fund LP, (ii) NEXTBio Capital Management LP, the investment manager to NEXTBio Master Fund LP, and (iii) Hongbo Lu, a managing member of NEXTBio Capital LLC. The Reporting Person disclaims beneficial ownership of the reported securities except to the extent of their pecuniary interest therein, and this report shall not be deemed an admission that the Reporting Person is the beneficial owners of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose."}],"balance_after":190476,"source":{"system":"sec-edgar","filing":"0000919574-24-005529","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1767584/000091957424005529/ownership.xml","form_type":"4"}},{"id":1406318,"issuer":{"id":275,"kind":"organization","name":"Zenas BioPharma, Inc.","symbol":"ZBIO"},"owners":[{"id":37101,"kind":"person","name":"Lu Hongbo","position":1,"cik":"0001767584","reported_name":"Lu Hongbo","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2024-09-17T01:01:52.000Z","date":"2024-09-12","kind":"grant","planned":false,"acquired":true,"shares":37000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option vests in equal annual installments over three years beginning on September 12, 2025, the first anniversary of the vesting commencement date, subject to continued service."}],"balance_after":37000,"derivative":{"exercise_price":17,"expiration_date":"2034-09-11","underlying":"Common Stock","underlying_shares":37000},"source":{"system":"sec-edgar","filing":"0001104659-24-100337","document":"tm2424157-10_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1767584/000110465924100337/tm2424157-10_4seq1.xml","form_type":"4"}},{"id":1461997,"issuer":{"id":49595,"kind":"organization","name":"Terns Pharmaceuticals, Inc.","symbol":"TERN"},"owners":[{"id":37101,"kind":"person","name":"Lu Hongbo","position":1,"cik":"0001767584","reported_name":"Lu Hongbo","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2024-07-02T22:36:57.000Z","date":"2024-07-01","kind":"grant","planned":false,"acquired":true,"shares":4676,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"This option was issued pursuant to the Issuer's Non-Employee Director Compensation Policy, under which the Reporting Person elected to receive this option in lieu of the Reporting Person's cash retainer fee of $20,000 for the third and fourth quarters of 2024."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The option will vest as to 1/6th of the total shares subject thereto on each monthly anniversary of the date of grant, such that 100% of the shares subject to the option will be fully vested on January 1, 2025."}],"balance_after":4676,"derivative":{"exercise_price":6.85,"expiration_date":"2034-06-30","underlying":"Common Stock","underlying_shares":4676},"source":{"system":"sec-edgar","filing":"0001562180-24-005548","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1767584/000156218024005548/primarydocument.xml","form_type":"4"}},{"id":1478398,"issuer":{"id":49595,"kind":"organization","name":"Terns Pharmaceuticals, Inc.","symbol":"TERN"},"owners":[{"id":37101,"kind":"person","name":"Lu Hongbo","position":1,"cik":"0001767584","reported_name":"Lu Hongbo","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2024-06-14T22:04:49.000Z","date":"2024-06-10","kind":"grant","planned":false,"acquired":true,"shares":32000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option will vest in full on the earlier of (i) the first anniversary of the date of grant and (ii) immediately prior to the Annual Meeting following the date of grant."}],"balance_after":32000,"derivative":{"exercise_price":6.99,"expiration_date":"2034-06-09","underlying":"Common Stock","underlying_shares":32000},"source":{"system":"sec-edgar","filing":"0001562180-24-005104","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1767584/000156218024005104/primarydocument.xml","form_type":"4"}},{"id":1566494,"issuer":{"id":3472,"kind":"organization","name":"ARROWHEAD PHARMACEUTICALS, INC."},"owners":[{"id":37101,"kind":"person","name":"Lu Hongbo","position":1,"cik":"0001767584","reported_name":"Lu Hongbo","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-03-20T23:06:58.000Z","date":"2024-03-20","kind":"purchase","planned":false,"acquired":true,"shares":1000,"price":27.5,"value":27500.0,"ownership":{"direct":true},"balance_after":33680,"source":{"system":"sec-edgar","filing":"0001628280-24-012327","document":"wk-form4_1710976009.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/879407/000162828024012327/wk-form4_1710976009.xml","form_type":"4"}},{"id":1566493,"issuer":{"id":3472,"kind":"organization","name":"ARROWHEAD PHARMACEUTICALS, INC."},"owners":[{"id":37101,"kind":"person","name":"Lu Hongbo","position":1,"cik":"0001767584","reported_name":"Lu Hongbo","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-03-20T23:06:58.000Z","date":"2024-03-19","kind":"purchase","planned":false,"acquired":true,"shares":1000,"price":28,"value":28000.0,"ownership":{"direct":true},"balance_after":32680,"source":{"system":"sec-edgar","filing":"0001628280-24-012327","document":"wk-form4_1710976009.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/879407/000162828024012327/wk-form4_1710976009.xml","form_type":"4"}},{"id":1566492,"issuer":{"id":3472,"kind":"organization","name":"ARROWHEAD PHARMACEUTICALS, INC."},"owners":[{"id":37101,"kind":"person","name":"Lu Hongbo","position":1,"cik":"0001767584","reported_name":"Lu Hongbo","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-03-20T23:06:58.000Z","date":"2024-03-18","kind":"purchase","planned":false,"acquired":true,"shares":1000,"price":27.49,"value":27490.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported on Column 4 is the weighted average price. These shares were purchase in multiple transactions at prices ranging from $ 27.48 to $ 27.50, inclusive. The reporting person undertakes to provide to Arrowhead Pharmaceuticals, Inc., any security holder of Arrowhead Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote of this Form 4."}],"balance_after":31680,"source":{"system":"sec-edgar","filing":"0001628280-24-012327","document":"wk-form4_1710976009.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/879407/000162828024012327/wk-form4_1710976009.xml","form_type":"4"}},{"id":1855436,"issuer":{"id":49595,"kind":"organization","name":"Terns Pharmaceuticals, Inc.","symbol":"TERN"},"owners":[{"id":37101,"kind":"person","name":"Lu Hongbo","position":1,"cik":"0001767584","reported_name":"Lu Hongbo","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2023-06-14T23:01:27.000Z","date":"2023-06-12","kind":"grant","planned":false,"acquired":true,"shares":32000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option will vest in full on the earlier of (i) the first anniversary of the date of grant and (ii) immediately prior to the Annual Meeting following the date of grant."}],"balance_after":32000,"derivative":{"exercise_price":12.05,"expiration_date":"2033-06-11","underlying":"Common Stock","underlying_shares":32000},"source":{"system":"sec-edgar","filing":"0001562180-23-005168","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1767584/000156218023005168/primarydocument.xml","form_type":"4"}},{"id":2076540,"issuer":{"id":49595,"kind":"organization","name":"Terns Pharmaceuticals, Inc.","symbol":"TERN"},"owners":[{"id":37101,"kind":"person","name":"Lu Hongbo","position":1,"cik":"0001767584","reported_name":"Lu Hongbo","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-12-23T22:44:17.000Z","date":"2022-12-23","kind":"purchase","acquired":true,"shares":758620,"price":7.25,"value":5499995.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"The securities are held of record by Vivo Opportunity Fund Holdings, L.P.  Vivo Opportunity, LLC is the general partner of Vivo Opportunity Fund Holdings, L.P.  As a managing member of Vivo Opportunity, LLC, Hongbo Lu shares voting and dispositive power over the securities held by Vivo Opportunity Fund Holdings, L.P. with four other managing members but disclaims beneficial ownership over such securities except to the extent of her pecuniary interest therein."}],"balance_after":4340212,"source":{"system":"sec-edgar","filing":"0001562180-22-008428","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1767584/000156218022008428/primarydocument.xml","form_type":"4"}},{"id":2162854,"issuer":{"id":49595,"kind":"organization","name":"Terns Pharmaceuticals, Inc.","symbol":"TERN"},"owners":[{"id":37101,"kind":"person","name":"Lu Hongbo","position":1,"cik":"0001767584","reported_name":"Lu Hongbo","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-09-09T00:00:37.000Z","date":"2022-09-07","kind":"purchase","acquired":true,"shares":600000,"price":3.6,"value":2160000.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"The securities are held of record by Vivo Opportunity Fund Holdings, L.P.  Vivo Opportunity, LLC is the general partner of Vivo Opportunity Fund Holdings, L.P.  As a managing member of Vivo Opportunity, LLC, Hongbo Lu shares voting and dispositive power over the securities held by Vivo Opportunity Fund Holdings, L.P. with four other managing members but disclaims beneficial ownership over such securities except to the extent of her pecuniary interest therein."}],"balance_after":3581592,"source":{"system":"sec-edgar","filing":"0001562180-22-006567","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1767584/000156218022006567/primarydocument.xml","form_type":"4"}},{"id":2183556,"issuer":{"id":49595,"kind":"organization","name":"Terns Pharmaceuticals, Inc.","symbol":"TERN"},"owners":[{"id":37101,"kind":"person","name":"Lu Hongbo","position":1,"cik":"0001767584","reported_name":"Lu Hongbo","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Pre-funded Warrants (right to buy)","published_at":"2022-08-17T00:30:26.000Z","date":"2022-08-16","kind":"purchase","acquired":true,"shares":1500000,"price":2.4199,"value":3629850.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F4","text":"Vivo Opportunity Fund Holdings, L.P. acquired 1,500,000 shares of Common Stock at $2.42 per share and 1,500,000 pre-funded warrants at $2.4199 per warrant in an underwritten offering."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"The pre-funded warrants have no expiration date and are exercisable immediately, subject to a 4.99% beneficial ownership limit."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"The pre-funded warrants have no expiration date and are exercisable immediately, subject to a 4.99% beneficial ownership limit."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The securities are held of record by Vivo Opportunity Fund Holdings, L.P.  Vivo Opportunity, LLC is the general partner of Vivo Opportunity Fund Holdings, L.P.  As a managing member of Vivo Opportunity, LLC, Hongbo Lu shares voting and dispositive power over the securities held by Vivo Opportunity Fund Holdings, L.P. with four other managing members but disclaims beneficial ownership over such securities except to the extent of her pecuniary interest therein."}],"balance_after":1500000,"derivative":{"exercise_price":0.0001,"underlying":"Common Stock","underlying_shares":1500000},"source":{"system":"sec-edgar","filing":"0001562180-22-006125","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1767584/000156218022006125/primarydocument.xml","form_type":"4"}},{"id":2183555,"issuer":{"id":49595,"kind":"organization","name":"Terns Pharmaceuticals, Inc.","symbol":"TERN"},"owners":[{"id":37101,"kind":"person","name":"Lu Hongbo","position":1,"cik":"0001767584","reported_name":"Lu Hongbo","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-08-17T00:30:26.000Z","date":"2022-08-16","kind":"purchase","acquired":true,"shares":1500000,"price":2.42,"value":3630000.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F4","text":"Vivo Opportunity Fund Holdings, L.P. acquired 1,500,000 shares of Common Stock at $2.42 per share and 1,500,000 pre-funded warrants at $2.4199 per warrant in an underwritten offering."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Vivo Opportunity Fund Holdings, L.P. acquired 1,500,000 shares of Common Stock at $2.42 per share and 1,500,000 pre-funded warrants at $2.4199 per warrant in an underwritten offering."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The securities are held of record by Vivo Opportunity Fund Holdings, L.P.  Vivo Opportunity, LLC is the general partner of Vivo Opportunity Fund Holdings, L.P.  As a managing member of Vivo Opportunity, LLC, Hongbo Lu shares voting and dispositive power over the securities held by Vivo Opportunity Fund Holdings, L.P. with four other managing members but disclaims beneficial ownership over such securities except to the extent of her pecuniary interest therein."}],"balance_after":2981592,"source":{"system":"sec-edgar","filing":"0001562180-22-006125","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1767584/000156218022006125/primarydocument.xml","form_type":"4"}},{"id":2183554,"issuer":{"id":49595,"kind":"organization","name":"Terns Pharmaceuticals, Inc.","symbol":"TERN"},"owners":[{"id":37101,"kind":"person","name":"Lu Hongbo","position":1,"cik":"0001767584","reported_name":"Lu Hongbo","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-08-17T00:30:26.000Z","date":"2022-08-15","kind":"purchase","acquired":true,"shares":1218,"price":2.99,"value":3641.82,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported herein is a weighted average price. These shares were acquired on the open market in multiple transactions at prices ranging from $2.96 to $3.00, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares acquired at each separate price within the ranges set forth in footnote (3) to this Form 4."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The securities are held of record by Vivo Opportunity Fund Holdings, L.P.  Vivo Opportunity, LLC is the general partner of Vivo Opportunity Fund Holdings, L.P.  As a managing member of Vivo Opportunity, LLC, Hongbo Lu shares voting and dispositive power over the securities held by Vivo Opportunity Fund Holdings, L.P. with four other managing members but disclaims beneficial ownership over such securities except to the extent of her pecuniary interest therein."}],"balance_after":1481592,"source":{"system":"sec-edgar","filing":"0001562180-22-006125","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1767584/000156218022006125/primarydocument.xml","form_type":"4"}},{"id":2183553,"issuer":{"id":49595,"kind":"organization","name":"Terns Pharmaceuticals, Inc.","symbol":"TERN"},"owners":[{"id":37101,"kind":"person","name":"Lu Hongbo","position":1,"cik":"0001767584","reported_name":"Lu Hongbo","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-08-17T00:30:26.000Z","date":"2022-08-12","kind":"purchase","acquired":true,"shares":1123021,"price":2.98,"value":3346602.58,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported herein is a weighted average price. These shares were acquired on the open market in multiple transactions at prices ranging from $2.83 to $3.02, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares acquired at each separate price within the ranges set forth in footnote (1) to this Form 4."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The securities are held of record by Vivo Opportunity Fund Holdings, L.P.  Vivo Opportunity, LLC is the general partner of Vivo Opportunity Fund Holdings, L.P.  As a managing member of Vivo Opportunity, LLC, Hongbo Lu shares voting and dispositive power over the securities held by Vivo Opportunity Fund Holdings, L.P. with four other managing members but disclaims beneficial ownership over such securities except to the extent of her pecuniary interest therein."}],"balance_after":1480374,"source":{"system":"sec-edgar","filing":"0001562180-22-006125","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1767584/000156218022006125/primarydocument.xml","form_type":"4"}},{"id":2224836,"issuer":{"id":49595,"kind":"organization","name":"Terns Pharmaceuticals, Inc.","symbol":"TERN"},"owners":[{"id":37101,"kind":"person","name":"Lu Hongbo","position":1,"cik":"0001767584","reported_name":"Lu Hongbo","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2022-06-22T01:00:13.000Z","date":"2022-06-16","kind":"grant","acquired":true,"shares":32000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option will vest in full on the earlier of (i) the first anniversary of the date of grant and (ii) immediately prior to the Annual Meeting following the date of grant."}],"balance_after":32000,"derivative":{"exercise_price":1.82,"expiration_date":"2032-06-15","underlying":"Common Stock","underlying_shares":32000},"source":{"system":"sec-edgar","filing":"0001562180-22-005265","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1767584/000156218022005265/primarydocument.xml","form_type":"4"}},{"id":2828819,"issuer":{"id":49595,"kind":"organization","name":"Terns Pharmaceuticals, Inc.","symbol":"TERN"},"owners":[{"id":37101,"kind":"person","name":"Lu Hongbo","position":1,"cik":"0001767584","reported_name":"Lu Hongbo","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2021-02-26T22:04:56.000Z","date":"2021-02-24","kind":"grant","acquired":true,"shares":25000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"1/3rd of the shares subject to the option vest on the first anniversary measured from February 24, 2021 (the \"Vesting Commencement Date\"), and 1/36th of the total number of shares vest on each monthly anniversary thereafter, such that 100% of the shares subject to the option will be fully vested and exercisable on the third anniversary of the Vesting Commencement Date."}],"balance_after":25000,"derivative":{"exercise_price":22.06,"expiration_date":"2031-02-23","underlying":"Common Stock","underlying_shares":25000},"source":{"system":"sec-edgar","filing":"0001567619-21-005069","document":"doc1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1767584/000156761921005069/doc1.xml","form_type":"4"}},{"id":3359805,"issuer":{"id":153528,"kind":"organization","name":"AVEDRO INC","symbol":"AVDR"},"owners":[{"id":37101,"kind":"person","name":"Lu Hongbo","position":1,"cik":"0001767584","reported_name":"Lu Hongbo","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Units","published_at":"2019-11-25T16:31:31.000Z","date":"2019-11-21","kind":"disposition_to_issuer","acquired":false,"shares":3005,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Each restricted stock unit (\"RSU\") represents a contingent right to receive one share of the Issuer's common stock."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"At the Effective Time, each outstanding restricted stock unit (\"Issuer RSU\") (excluding any Issuer RSU that vested prior to or as a result of the consummation of the Merger and which settled in shares of Issuer Common Stock that were converted into the right to receive shares of Parent Common Stock as a result of the Merger) was assumed by Parent and converted into the right to receive shares of Parent Common Stock (rounded down to the nearest whole share) using a conversion ratio designed to preserve the intrinsic value of such Issuer RSU."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"At the Effective Time, each outstanding restricted stock unit (\"Issuer RSU\") (excluding any Issuer RSU that vested prior to or as a result of the consummation of the Merger and which settled in shares of Issuer Common Stock that were converted into the right to receive shares of Parent Common Stock as a result of the Merger) was assumed by Parent and converted into the right to receive shares of Parent Common Stock (rounded down to the nearest whole share) using a conversion ratio designed to preserve the intrinsic value of such Issuer RSU."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"At the Effective Time, each outstanding restricted stock unit (\"Issuer RSU\") (excluding any Issuer RSU that vested prior to or as a result of the consummation of the Merger and which settled in shares of Issuer Common Stock that were converted into the right to receive shares of Parent Common Stock as a result of the Merger) was assumed by Parent and converted into the right to receive shares of Parent Common Stock (rounded down to the nearest whole share) using a conversion ratio designed to preserve the intrinsic value of such Issuer RSU."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":3005},"source":{"system":"sec-edgar","filing":"0001209191-19-057938","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1343304/000120919119057938/doc4.xml","form_type":"4"}},{"id":3359804,"issuer":{"id":153528,"kind":"organization","name":"AVEDRO INC","symbol":"AVDR"},"owners":[{"id":37101,"kind":"person","name":"Lu Hongbo","position":1,"cik":"0001767584","reported_name":"Lu Hongbo","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2019-11-25T16:31:31.000Z","date":"2019-11-21","kind":"disposition_to_issuer","acquired":false,"shares":8314,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"At the Effective Time, each outstanding and unexercised option to purchase Issuer Common Stock (whether vested or unvested) immediately prior to the Effective Time, was assumed by Parent and converted into an option to purchase shares of Parent Common Shares (rounded down to the nearest whole share) using a conversion ratio designed to preserve the intrinsic value of such option of Issuer."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"At the Effective Time, each outstanding and unexercised option to purchase Issuer Common Stock (whether vested or unvested) immediately prior to the Effective Time, was assumed by Parent and converted into an option to purchase shares of Parent Common Shares (rounded down to the nearest whole share) using a conversion ratio designed to preserve the intrinsic value of such option of Issuer."}],"balance_after":0,"derivative":{"exercise_price":12.73,"expiration_date":"2029-01-08","underlying":"Common Stock","underlying_shares":8314},"source":{"system":"sec-edgar","filing":"0001209191-19-057938","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1343304/000120919119057938/doc4.xml","form_type":"4"}},{"id":3485837,"issuer":{"id":153528,"kind":"organization","name":"AVEDRO INC","symbol":"AVDR"},"owners":[{"id":37101,"kind":"person","name":"Lu Hongbo","position":1,"cik":"0001767584","reported_name":"Lu Hongbo","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Units","published_at":"2019-06-18T19:50:05.000Z","date":"2019-06-14","kind":"grant","acquired":true,"shares":3005,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit (\"RSU\") represents a contingent right to receive one share of the Issuer's common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The RSUs vest on June 1, 2020, subject to Reporting Person's continuous service through such date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"The RSUs vest on June 1, 2020, subject to Reporting Person's continuous service through such date."}],"balance_after":3005,"derivative":{"underlying":"Common Stock","underlying_shares":3005},"source":{"system":"sec-edgar","filing":"0001209191-19-037845","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1343304/000120919119037845/doc4.xml","form_type":"4"}},{"id":3549878,"issuer":{"id":124461,"kind":"organization","name":"Turning Point Therapeutics, Inc.","symbol":"TPTX"},"owners":[{"id":37101,"kind":"person","name":"Lu Hongbo","position":1,"cik":"0001767584","reported_name":"Lu Hongbo","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Series D Preferred Stock","published_at":"2019-04-24T18:11:50.000Z","date":"2019-04-22","kind":"exercise","acquired":false,"shares":2105259,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By LAV Prime Limited"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Automatic conversion, in connection with the Issuer's initial public offering, of each share of preferred stock into 0.25974026 shares of common stock. The shares have no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Automatic conversion, in connection with the Issuer's initial public offering, of each share of preferred stock into 0.25974026 shares of common stock. The shares have no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Automatic conversion, in connection with the Issuer's initial public offering, of each share of preferred stock into 0.25974026 shares of common stock. The shares have no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The Reporting Person is a Partner at Lilly Asia Ventures and may be deemed to beneficially own the shares held by LAV Prime Limited."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":546820},"source":{"system":"sec-edgar","filing":"0001209191-19-025793","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1595893/000120919119025793/doc4.xml","form_type":"4"}},{"id":3549877,"issuer":{"id":124461,"kind":"organization","name":"Turning Point Therapeutics, Inc.","symbol":"TPTX"},"owners":[{"id":37101,"kind":"person","name":"Lu Hongbo","position":1,"cik":"0001767584","reported_name":"Lu Hongbo","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Series C Preferred Stock","published_at":"2019-04-24T18:11:50.000Z","date":"2019-04-22","kind":"exercise","acquired":false,"shares":4314809,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By LAV Prime Limited"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Automatic conversion, in connection with the Issuer's initial public offering, of each share of preferred stock into 0.25974026 shares of common stock. The shares have no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Automatic conversion, in connection with the Issuer's initial public offering, of each share of preferred stock into 0.25974026 shares of common stock. The shares have no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Automatic conversion, in connection with the Issuer's initial public offering, of each share of preferred stock into 0.25974026 shares of common stock. The shares have no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The Reporting Person is a Partner at Lilly Asia Ventures and may be deemed to beneficially own the shares held by LAV Prime Limited."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":1120730},"source":{"system":"sec-edgar","filing":"0001209191-19-025793","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1595893/000120919119025793/doc4.xml","form_type":"4"}},{"id":3549876,"issuer":{"id":124461,"kind":"organization","name":"Turning Point Therapeutics, Inc.","symbol":"TPTX"},"owners":[{"id":37101,"kind":"person","name":"Lu Hongbo","position":1,"cik":"0001767584","reported_name":"Lu Hongbo","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2019-04-24T18:11:50.000Z","date":"2019-04-22","kind":"grant","acquired":true,"shares":15000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The option will become fully vested on the date of the Issuer's 2020 annual meeting of stockholders."}],"balance_after":15000,"derivative":{"exercise_price":27.06,"expiration_date":"2029-04-21","underlying":"Common Stock","underlying_shares":15000},"source":{"system":"sec-edgar","filing":"0001209191-19-025793","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1595893/000120919119025793/doc4.xml","form_type":"4"}},{"id":3549875,"issuer":{"id":124461,"kind":"organization","name":"Turning Point Therapeutics, Inc.","symbol":"TPTX"},"owners":[{"id":37101,"kind":"person","name":"Lu Hongbo","position":1,"cik":"0001767584","reported_name":"Lu Hongbo","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2019-04-24T18:11:50.000Z","date":"2019-04-22","kind":"purchase","acquired":true,"shares":60000,"price":18,"value":1080000.0,"ownership":{"direct":false,"nature":"By LAV Prime Limited"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F3","text":"The shares were purchased at the Issuer's initial public offering."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The Reporting Person is a Partner at Lilly Asia Ventures and may be deemed to beneficially own the shares held by LAV Prime Limited."}],"balance_after":1727550,"source":{"system":"sec-edgar","filing":"0001209191-19-025793","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1595893/000120919119025793/doc4.xml","form_type":"4"}},{"id":3549874,"issuer":{"id":124461,"kind":"organization","name":"Turning Point Therapeutics, Inc.","symbol":"TPTX"},"owners":[{"id":37101,"kind":"person","name":"Lu Hongbo","position":1,"cik":"0001767584","reported_name":"Lu Hongbo","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2019-04-24T18:11:50.000Z","date":"2019-04-22","kind":"exercise","acquired":true,"shares":546820,"ownership":{"direct":false,"nature":"By LAV Prime Limited"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Automatic conversion, in connection with the Issuer's initial public offering, of each share of preferred stock into 0.25974026 shares of common stock. The shares have no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Automatic conversion, in connection with the Issuer's initial public offering, of each share of preferred stock into 0.25974026 shares of common stock. The shares have no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The Reporting Person is a Partner at Lilly Asia Ventures and may be deemed to beneficially own the shares held by LAV Prime Limited."}],"balance_after":1667550,"source":{"system":"sec-edgar","filing":"0001209191-19-025793","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1595893/000120919119025793/doc4.xml","form_type":"4"}},{"id":3549873,"issuer":{"id":124461,"kind":"organization","name":"Turning Point Therapeutics, Inc.","symbol":"TPTX"},"owners":[{"id":37101,"kind":"person","name":"Lu Hongbo","position":1,"cik":"0001767584","reported_name":"Lu Hongbo","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2019-04-24T18:11:50.000Z","date":"2019-04-22","kind":"exercise","acquired":true,"shares":1120730,"ownership":{"direct":false,"nature":"By LAV Prime Limited"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Automatic conversion, in connection with the Issuer's initial public offering, of each share of preferred stock into 0.25974026 shares of common stock. The shares have no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Automatic conversion, in connection with the Issuer's initial public offering, of each share of preferred stock into 0.25974026 shares of common stock. The shares have no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The Reporting Person is a Partner at Lilly Asia Ventures and may be deemed to beneficially own the shares held by LAV Prime Limited."}],"balance_after":1120730,"source":{"system":"sec-edgar","filing":"0001209191-19-025793","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1595893/000120919119025793/doc4.xml","form_type":"4"}},{"id":3649146,"issuer":{"id":153528,"kind":"organization","name":"AVEDRO INC","symbol":"AVDR"},"owners":[{"id":37101,"kind":"person","name":"Lu Hongbo","position":1,"cik":"0001767584","reported_name":"Lu Hongbo","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2019-02-19T19:13:28.000Z","date":"2019-02-19","kind":"grant","acquired":true,"shares":8314,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"One hundred percent (100%) of the shares subject to the option shall vest on the earlier of (x) June 1, 2020 and (y) the first anniversary of the first annual meeting of the Issuer's stockholders following the Issuer's initial public offering, subject to the Reporting Person continuing to provide service through such date."}],"balance_after":8314,"derivative":{"exercise_price":12.73,"expiration_date":"2029-01-08","underlying":"Common Stock","underlying_shares":8314},"source":{"system":"sec-edgar","filing":"0001209191-19-011334","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1343304/000120919119011334/doc4.xml","form_type":"4"}}]}